Your browser doesn't support javascript.
Antisense oligonucleotide: A promising therapeutic option to beat COVID-19.
Quemener, Anaïs M; Galibert, Marie-Dominique.
  • Quemener AM; Univ Rennes, CNRS, IGDR (Institute of Genetics and Development of Rennes) - UMR 6290, Rennes, France.
  • Galibert MD; Univ Rennes, CNRS, IGDR (Institute of Genetics and Development of Rennes) - UMR 6290, Rennes, France.
Wiley Interdiscip Rev RNA ; 13(4): e1703, 2022 07.
Article in English | MEDLINE | ID: covidwho-2277282
ABSTRACT
The COVID-19 crisis and the development of the first approved mRNA vaccine have highlighted the power of RNA-based therapeutic strategies for the development of new medicines. Aside from RNA-vaccines, antisense oligonucleotides (ASOs) represent a new and very promising class of RNA-targeted therapy. Few drugs have already received approval from the Food and Drug Administration. Here, we underscored why and how ASOs hold the potential to change the therapeutic landscape to beat SARS-CoV-2 viral infections. This article is categorized under RNA Interactions with Proteins and Other Molecules > Small Molecule-RNA Interactions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Oligonucleotides, Antisense / COVID-19 Drug Treatment Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Wiley Interdiscip Rev RNA Year: 2022 Document Type: Article Affiliation country: Wrna.1703

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Oligonucleotides, Antisense / COVID-19 Drug Treatment Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Wiley Interdiscip Rev RNA Year: 2022 Document Type: Article Affiliation country: Wrna.1703